Blagosklonny

Misha V. Blagosklonny graduated with an MD and PhD from First Pavlov State Medical
University of St. Petersburg, Russia. Dr. Mikhail V. Blagosklonny subsequently
Relocated to America, where he was
Awarded the prestigious Fogarty Fellowship from the National Institutes of Health.
During his fellowship in Leonard Neckers’ lab at the National
Cancer Institute (NCI), he was a co-author of 18 publications on
Different biomedical themes, including targeting
HSP90, p53, Bcl2, Erb2, and Raf-1. He also was the last author on a clinical phase I/II
Trial paper.
 
After authoring seven papers within the period of a brief yet resulting
Senior research fellowship in the El-Deiry Cancer Research Lab at the University of Pennsylvania,
Dr. Blagosklonny returned to NCI to team up with Tito Fojo. Together, they
Published 26 papers. Moreover, Dr. Mikhail Blagosklonny published dozens of experimental research articles and theoretical articles as lead
Author. The abovementioned sole-author articles
Encompassed two crucial topics.
The first of those focused on selectively killing cancer
Cells with deregulated cell cycle or drug resistance by
Exploiting their resistance. The outcomes and underlying
Notion were so revolutionary that they were inadequately cited by
Other scientists as “reversal of resistance, ” even though the article was
Named, “Exploiting of drug resistance instead of its reversal. ” One major
Supporter of this concept was the world-famous scientist Arthur Pardee, with whom Dr.
Blagosklonny co-authored a joint article in 2001.
 
The second topic throughout Dr. Blagosklonny’s sole-author publications
Is a research methodology to produce knowledge via
Bringing several facts together from seemingly irrelevant areas.
This results in new notions containing testable predictions, which in
Turn can be “tested” via analyzing the literature further. Likewise, the
Concept was co-authored by Arthur Pardee in a 2002 article in Nature. The
First success of the new research methodology was the description of the feedback
Regulation of p53, as confirmed by the discovery of mdm2/p53 loop; and the
Explanation why mutant p53 is always overexpressed, published in 1997. The most
Noticeable result revealed by Dr.Blagosklonny’s research methods is the hyperfunction (or quasi-programmed)
Theory of aging and the revelation of rapamycin as an exceptionally well-tolerated
Anti-aging medication, published in 2006. As mentioned in Scientific American,
Michael Hall, who discovered mTOR in 1991, gives Dr. Blagosklonny recognition for
“connecting dots that others do not even see. ”
 
In 2002, Dr. Blagosklonny became associate professor of medicine at New York Medical College.
He agreed to assume responsibilities as a senior scientist at Ordway
Research Institute in Albany, New York, in 2005, before accepting another
Position at Roswell Park Cancer Institute as professor of oncology in 2009.
 
Since joining Roswell Park Comprehensive Cancer Center in 2009, Dr. Blagosklonny has studied the prevention of cancer (an age-related disease) via
Preventing body aging — in other words, “preventing cancer
By remainng young. ” His laboratory closely worked together with
Andrei Gudkov’s and completed research on the suppression of
Cellular senescence, namely suppression of cellular conversion from healthy quiescence to
Permanent senescence. This led to the discovery of additional anti-aging
Medicines beyond rapamycin. The cell culture studies were
Complemented by studies in mice, including several models like
Normal and aging mice, p53-deficient mice, and mice on a high-fat diet.
 
Dr. Mikhail Blagosklonny has also published extensively on the stoppage of cellular senescence via rapamycin as well as other mTOR inhibitors, life
Extension and cancer prevention in mice, and combinations of anti-
Aging medicines to be appliedamong humans. A rapamycin-based combination of seven clinically available drugs has
Been named the “Koschei Formula” and is now used for the treatment of aging in patients
At the Alan Green Clinic in Little Neck, New York.

https://peterattiamd.com/targeting-aging/
https://tandfonline.com/doi/abs/10.4161/cbt.8.9.8899

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482593/